scholarly journals Diagnosis and Management of Valvular Aortic Stenosis

2014 ◽  
Vol 8s1 ◽  
pp. CMC.S15716 ◽  
Author(s):  
Matthew J. Czarny ◽  
Jon R. Resar
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
The United States ◽  
Surgical Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Rate Of Progression ◽  
Valvular Aortic Stenosis ◽  
Cardinal Symptoms

Valvular aortic stenosis (AS) is a progressive disease that affects 2% of the population aged 65 years or older. The major cause of valvular AS in adults is calcification and fibrosis of a previously normal tricuspid valve or a congenital bicuspid valve, with rheumatic AS being rare in the United States. Once established, the rate of progression of valvular AS is quite variable and impossible to predict for any particular patient. Symptoms of AS are generally insidious at onset, though development of any of the three cardinal symptoms of angina, syncope, or heart failure portends a poor prognosis. Management of symptomatic AS remains primarily surgical, though transcatheter aortic valve replacement (TAVR) is becoming an accepted alternative to surgical aortic valve replacement (SAVR) for patients at high or prohibitive operative risk.

Economic Considerations in Access to Transcatheter Aortic Valve Replacement

2022 ◽  
Author(s):  
Kriyana P. Reddy ◽  
Peter W. Groeneveld ◽  
Jay Giri ◽  
Alexander C. Fanaroff ◽  
Ashwin S. Nathan
Keyword(s):  
United States ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
The United States ◽  
Socioeconomically Disadvantaged ◽  
Transcatheter Aortic Valve ◽  
Economic Considerations

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, with the number of procedures and sites offering the procedure steadily rising over the past decade in the United States. Despite this, growth into certain markets has been limited as hospitals have to balance high TAVR costs with the ability to offer a complete array of state-of-the-art therapies for aortic stenosis. This trade-off often results in decreased access to TAVR services by patients cared for in hospitals that cannot afford these services or have difficulty meeting procedural requirements, recruiting skilled physicians, and initiating and then maintaining a functioning TAVR program. The lack of access is more common among patients of color or those who are socioeconomically disadvantaged. The purpose of this review is to describe the hospital-level economic considerations of TAVR in the United States and the resulting effects on geographic, racial, ethnic, and socioeconomic access for Americans.

Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis

2021 ◽  
Vol 17 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Samin K Sharma ◽  
Ravinder S Rao ◽  
Manik Chopra ◽  
Anmol Sonawane ◽  
John Jose ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Heart Valve ◽  
Future Research ◽  
Surgical Aortic Valve Replacement ◽  
Surgical Risk ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve

The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems. Myval™ THV (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India) is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes. This review summarizes existing preclinical and clinical data on Myval THV for the intervention of symptomatic native AS and lays out the plan for future research program.

Transcatheter Aortic Valve Replacements: Current Trends and Future Directions

2018 ◽  
Vol 23 (3) ◽  
pp. 282-292
Author(s):  
Lee A. Goeddel ◽  
Jessica Serini ◽  
Johannes W. Steyn ◽  
Adam S. Evans ◽  
Sanjay Dwarakanath ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
The United States ◽  
Surgical Aortic Valve Replacement ◽  
Future Directions ◽  
Continuous Growth ◽  
Hybrid Techniques ◽  
Transcatheter Aortic Valve ◽  
Surgical Access

Since the 1960s when the first aortic surgical aortic valve replacement (SAVR) was performed, continuous growth in the field of valvular technology has occurred. Although SAVR remains a lifesaving procedure, minimally invasive transcatheter aortic valve replacement has revolutionized and expanded aortic valve replacement to patients who were not previously SAVR candidates, increasing their quality of life and survival. Since its introduction in the United States in 2011, the technology and practice have rapidly expanded. Hybrid techniques have been developed that combine surgical access to the vasculature with valvular deployment over transcatheter systems. This literature review aims to describe the differences between the current available valve technologies, review approaches to surgical technique, discuss anesthetic considerations, and look forward to future directions, trends, and challenges.

Successful transcarotid transcatheter aortic valve replacement in a 34-kg patient with Schimke immuno-osseous dysplasia and severe biscuspid aortic stenosis

2018 ◽  
Vol 28 (7) ◽  
pp. 974-977
Author(s):  
Katie E. O’ Sullivan ◽  
Alan P. Griffin ◽  
Ivan P. Casserly
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Team Approach ◽  
Genetic Syndromes ◽  
Surgical Aortic Valve Replacement ◽  
Transcatheter Aortic Valve ◽  
Osseous Dysplasia

AbstractWe present the case of transcatheter aortic valve replacement in a 20-year-old woman with severe bicuspid aortic stenosis and Schmike immuno-osseous dysplasia who was unfit for surgical aortic valve replacement. Meticulous pre-procedural planning and a multidisciplinary team approach can enable successful transcatheter aortic valve replacement in complex patients with genetic syndromes.

Sign in / Sign up

Export Citation Format

Share Document